THERACRYF PLC (TCF) — Half year results for the six months to 30 September 2025

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the THERACRYF PLC Half Year Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Hugh Jones. Good morning to you. Thanks, Alex, and good morning, everybody. Thanks for attending our half year report investor meet, webinar. With me here in London is our chair, Alastair, our CFO, Tony, and our COO, Helen. We're very excited. We've come more handed because we're very excited about the progress we've made in a relatively short period on our now lead asset. But before we start in earnest, we are a public company. We're aim listed because the usual disclaimers will apply. So to remind you then, first, before we get to the news that has excited us greatly in this half year, we'll remind you of who we are. We're aim listed tcf.l. We're a brain focused biotech with a relatively recent at the start of this period refocus. So the key areas for us now are addiction, very certainly with our OX1 or Orexin one blocker, an antagonist of the Orexin one brain system. It's completely novel. Patents are granted across the world. It's suitable because it switches off a fundamental network in the brain, in a number of different addictive conditions, so called substance use disorders. And those substances are f...